• Publications
  • Influence
Oral anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.
BACKGROUND The objective of this article is to summarize the published literature concerning the pharmacokinetics and pharmacodynamics of oral anticoagulant drugs that are currently available forExpand
  • 1,124
  • 67
  • PDF
Oral rivaroxaban for symptomatic venous thromboembolism.
BACKGROUND Rivaroxaban, an oral factor Xa inhibitor, may provide a simple, fixed-dose regimen for treating acute deep-vein thrombosis (DVT) and for continued treatment, without the need forExpand
  • 1,982
  • 66
  • PDF
Oral apixaban for the treatment of acute venous thromboembolism.
BACKGROUND Apixaban, an oral factor Xa inhibitor administered in fixed doses, may simplify the treatment of venous thromboembolism. METHODS In this randomized, double-blind study, we comparedExpand
  • 1,536
  • 63
  • PDF
Apixaban for extended treatment of venous thromboembolism.
BACKGROUND Apixaban, an oral factor Xa inhibitor that can be administered in a simple, fixed-dose regimen, may be an option for the extended treatment of venous thromboembolism. METHODS In thisExpand
  • 932
  • 43
  • PDF
Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): a randomised double-blind trial
BACKGROUND Low-molecular-weight heparins such as enoxaparin are preferred for prevention of venous thromboembolism after major joint replacement. Apixaban, an orally active factor Xa inhibitor, mightExpand
  • 684
  • 34
  • PDF
Apixaban or enoxaparin for thromboprophylaxis after knee replacement.
BACKGROUND The optimal strategy for thromboprophylaxis after major joint replacement has not been established. Low-molecular-weight heparins such as enoxaparin predominantly target factor Xa but toExpand
  • 642
  • 28
Efficacy and safety of fondaparinux for the prevention of venous thromboembolism in older acute medical patients: randomised placebo controlled trial
Abstract Objective To determine the efficacy and safety of the anticoagulant fondaparinux in older acute medical inpatients at moderate to high risk of venous thromboembolism. Design Double blindExpand
  • 729
  • 26
  • PDF
Apixaban versus enoxaparin for thromboprophylaxis after hip replacement.
BACKGROUND There are various regimens for thromboprophylaxis after hip replacement. Low-molecular-weight heparins such as enoxaparin predominantly inhibit factor Xa but also inhibit thrombin to someExpand
  • 658
  • 25
Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home. The Tasman Study
BACKGROUND An intravenous course of standard (unfractionated) heparin with the dose adjusted to prolong the activated partial-thromboplastin time to a desired length is the standard initialExpand
  • 1,058
  • 17
Oral rivaroxaban for the treatment of symptomatic pulmonary embolism.
BACKGROUND A fixed-dose regimen of rivaroxaban, an oral factor Xa inhibitor, has been shown to be as effective as standard anticoagulant therapy for the treatment of deep-vein thrombosis, without theExpand
  • 1,581
  • 16
  • PDF
...
1
2
3
4
5
...